SEC Form 4 · accession 0001179110-18-008618
Syros Pharmaceuticals, Inc. · SYRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael W Bonney
Director
Period of report
Jun 14, 2018
Accepted (ET)
Jun 15, 2018 · 4:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001556263
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $12.95 | Jun 14, 2018 | A | 13,000 | A | — | Jun 13, 2028 | Common Stock | 13,000 | 13,000 | D |
Explanation of responses
- F1The option becomes exercisable as to 16.66% of the shares underlying the award on the six month anniversary of the grant date, with the remainder vesting in equal monthly installments until the third anniversary of the grant date, subject to Mr. Bonney's continued service as a director through each applicable vesting date.